Key Points
- CEO Abraham Ceesay sold 8,210 shares of Rapport Therapeutics at an average price of $45.61, worth approximately $374,458. He retains 458,977 shares, and the sale reduced his direct ownership by 1.76%.
- RAPP shares opened at $43.88 after falling 4.8%; the company recently reported a quarterly loss of $1.19 per share, missing analysts’ $1.12-loss estimate.
- Analyst sentiment remains broadly positive, with a consensus “Buy” rating and a $62.86 price target, while several institutional investors—including Johnson & Johnson and Algert Global—recently initiated positions.
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) CEO Abraham Ceesay sold 8,210 shares of the firm's stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $45.61, for a total transaction of $374,458.10. Following the transaction, the chief executive officer directly owned 458,977 shares of the company's stock, valued at $20,933,940.97. The trade was a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Abraham Ceesay also recently made the following trade(s):
- On Tuesday, August 25th, Abraham Ceesay sold 18,921 shares of Rapport Therapeutics stock. The shares were sold at an average price of $49.57, for a total transaction of $937,913.97.
- On Tuesday, August 11th, Abraham Ceesay sold 28,958 shares of Rapport Therapeutics stock. The shares were sold at an average price of $48.01, for a total transaction of $1,390,273.58.
- On Monday, August 10th, Abraham Ceesay sold 22,541 shares of Rapport Therapeutics stock. The stock was sold at an average price of $46.26, for a total transaction of $1,042,746.66.
- On Monday, July 27th, Abraham Ceesay sold 2,210 shares of Rapport Therapeutics stock. The stock was sold at an average price of $42.11, for a total transaction of $93,063.10.
Rapport Therapeutics Stock Down 4.8%
Shares of RAPP opened at $43.88 on Thursday. The company has a 50-day moving average price of $44.55 and a two-hundred day moving average price of $37.97. The stock has a market cap of $2.11 billion, a price-to-earnings ratio of -14.43 and a beta of 1.02. Rapport Therapeutics, Inc. has a 12 month low of $22.06 and a 12 month high of $52.93.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.19) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.07). Equities research analysts expect that Rapport Therapeutics, Inc. will post -4.09 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of RAPP. Algert Global LLC acquired a new position in Rapport Therapeutics during the 2nd quarter worth $9,327,000. Johnson & Johnson acquired a new stake in shares of Rapport Therapeutics in the 2nd quarter valued at $74,360,823. Walleye Capital LLC acquired a new stake in shares of Rapport Therapeutics in the 2nd quarter valued at $4,257,000. Dimensional Fund Advisors LP raised its position in shares of Rapport Therapeutics by 168.9% during the first quarter. Dimensional Fund Advisors LP now owns 224,498 shares of the company's stock worth $7,025,000 after acquiring an additional 141,011 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of Rapport Therapeutics by 23.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 3,001,879 shares of the company's stock worth $91,077,000 after acquiring an additional 579,903 shares during the last quarter.
Wall Street Analysts Forecast Growth
RAPP has been the topic of a number of analyst reports. Leerink Partners assumed coverage on Rapport Therapeutics in a research report on Wednesday, June 24th. They issued an "outperform" rating and a $52.00 price target on the stock. Raymond James Financial reissued a "strong-buy" rating and set a $75.00 price objective on shares of Rapport Therapeutics in a report on Monday, August 17th. Wall Street Zen downgraded shares of Rapport Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Rapport Therapeutics in a report on Friday, July 17th. Finally, HC Wainwright increased their target price on shares of Rapport Therapeutics from $40.00 to $66.00 and gave the stock a "buy" rating in a research report on Wednesday, August 12th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Rapport Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $62.86.
Get Our Latest Stock Report on RAPP
Rapport Therapeutics Company Profile
(
Get Free Report)
Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.
Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
